ABSTRACT
INTRODUCTION
During food digestion, proteins render a large variety of different peptides. Some of these sequences are structurally similar to endogenous physiologically active peptides and therefore, these food-derived sequences can interact with the same receptors in the organism, exerting an agonist or antagonist activity. One of the best examples where this applies, are food-derived opioid peptides, i.e., exogenous opioid receptor ligands with agonistic activity.
From milk, peptides derived from β-casein, referred as β-casomorphins, were the first food protein-derived opioid receptor ligands whose sequences were identified (Brantl, Teschemacher, Henschen, & Lottspeich, 1979) . They have been found in in vivo digestion products from humans and minipigs (Barbé et al., 2014; Boutrou et al., 2013) . The common structural characteristics of both, exogenous and endogenous opioid peptides, are the presence of a tyrosine residue at the N-terminus and the presence of other aromatic residue, phenylalanine or tyrosine, in the third or fourth position (Meisel, 1997) . In case of the α s1 -casein derived peptides or α-casein exorphins, the active sequence can contain an additional arginine residue at the N-terminus. Although caseins are source of many peptides showing agonist or antagonist action on different opioid receptors, opioid peptides from other protein sources have been also described, such as whey proteins (Antila et al., 1991) and hemoglobin (Zhao, Garreau, Sannier, & Piot, 1997) from animal sources and gluten, rice, or soy from plant proteins (Yoshikawa, 2015) .
Biological activities observed for these food-derived opioid sequences include analgesia and modulation of social behaviour, after parenteral or intracerebral administration to animals. Orally administered food-derived opioid peptides have demonstrated to influence postprandial metabolism by stimulating secretion of insulin and somatostatin, prolongation of gastrointestinal transit time, stimulation of food intake, and effects on the immune system, among others (for reviews regarding biological activity, see Meisel & FitzGerald, 2000; Rutherfurd-Markwick, 2012; Teschemacher, 2003; Teschemacher, Koch & Brantl, 1997) .
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Moreover, it was found that the opioid peptide β-casomorphin-7 (   60   YPFPGPI   66 ) induced intestinal mucin release through a nervous pathway and opioid receptor activation in ex-vivo preparations of rat jejunum (Claustre et al., 2002; Trompette et al., 2003) . In human (HT29-MTX) and rat (DHE) intestinal mucin-producing cells, this peptide increased secretion and expression of mucin, and these effects were prevented with the μ-opioid antagonist cyprodime (Zoghbi et al., 2006) . Similar effects were reported for the μ-opioid ligands, α- (Martínez-Maqueda, Miralles, Cruz-Huerta, Recio, 2013a) . Interestingly, these two peptides had been identified in in vivo gastric and duodenal human digests after milk ingestion (Chabance et al., 1998) . However, despite the favourable structure of these sequences and their potential to interact with opioid receptors located at the intestinal tract, the opioid activity of these peptides has not been previously demonstrated. The objective of this work was to investigate the opioid effect of the bovine α s1 -casein fragment   143   AYFYPEL   149 , and four derived peptides comprising the core structure for opioid activity YFY in guinea pig ileum and mouse vas deferens preparations. A molecular docking of two peptides into the active site of the μ-opioid receptor was carried out to identify the key residues responsible for the affinity to 5 the receptor. In addition, a preliminary study of these sequences on MUC5AC gene overexpression in HT29-MTX cells is shown. In the peptide purification protocol, the treatment with acetic acid was included to replace trifluoroacetic acid which affects the pH of the peptide solutions in the bioassays. Their purity (>90%) was verified in our laboratory by reverse phase high performance liquid chromatography and tandem mass spectrometry (HPLC-MS/MS).
MATERIALS AND METHODS

Peptides
Isolated preparations from guinea pig ileum and mouse vas deferens
Female guinea-pigs weighing 300-450 g, and male CD-1 mice weighing 25-60 g were used. Myenteric plexus-longitudinal muscle strips (MP-LM) from guinea pig ileum, and the mouse vas deferens were isolated as described by Ambache (1954) and Hughes et al. (1975) , respectively. Tissues were suspended in a 10 ml organ bath containing 5 ml of Krebs solution (NaCl 118, KCl 4.75, CaCl 2 2.54, KH 2 PO 4 1.19; MgSO 4 1.2; NaHCO 3 25; glucose 11mM). This solution was continuously gassed with 95% O 2 and 5% CO 2 . Tissues were kept under 1 g (guinea pig ileum) or 0.5 g (mouse vas deferens) of resting tension, at 37 ºC and were electrically stimulated through two platinum ring electrodes. MP-LM strips were stimulated with rectangular pulses of 70 V, 0.1 ms duration and 0.3 Hz frequency, and mouse vas deferens with trains of 15 rectangular pulses of 70 V, 15 Hz and 2 ms duration each min. The isometric force was monitored by computer using a MacLab data recording and analysis system. In both 6 assays the interval between applications of increasing concentrations was optimized to obtain a stable signal, and it was 9 min for α s1 -casein peptides, and 3 min when control opioid agonists were tested. To evaluate the opioid-agonistic activity of peptides in the guinea pig ileum, cumulative concentration-response curves with five doses in the range 6.1 × 10 -8 -1.0 × 10 -5 M were constructed in a step by step manner as follows: after 15 min-stabilisation of MP-LM strips in organ bath, electrical stimulation was applied, and peptide´s effect on the electrically induced contractions was evaluated once the response reached a plateau.
Morphine was used as µ-opioid agonist positive control. To corroborate that the inhibitory effect of the peptides was mediated through interaction with opioid receptors, one dose of naloxone (1.0 × 10 -6 M, Sigma), an non-selective opioid antagonist, was added to the organ bath at the end of each experiment. In mouse vas deferens preparations, non-cumulative concentration-response curves with four doses in the range 5.5 × 10 -7 -1.0 × 10 -5 M were tested. Once tissue stabilisation, the first peptide dose was added and evaluated. The tissue was then washed, and subsequent doses were applied. In this preparation, [D-Pen(2),DPen(5)]-enkephalin (DPDPE) was used as δ-opioid agonist, and one dose of naltrindole (1.0 × 10 -9 -1.0 × 10 -7 M, Sigma), a δ-selective opioid antagonist, was added after the experiments to evaluate selective interaction with δ-opioid receptors. Results were expressed as % of inhibition, taking the mean amplitude of the last five contractions before the addition of the peptides as 100%. In guinea pig ileum, when the effect of peptidase inhibitors (captopril, amastatin and phosphoramidon 1.0 × 10 -6 M, Sigma) was evaluated, they were added 5 min before the beginning of the peptide´s concentration-response curve (Akahori et al., 2008) .
Each tissue was employed only once, with at least six biological replicates per condition.
Experimental protocols used in this investigation were approved by the Ethical Committee of Rey Juan Carlos University. Data were analyzed using GraphPad Prism 5.03 software by a oneway ANOVA, followed by the Bonferroni Multiple Comparison test. Differences between each dose with a P value < 0.05 were considered significant.
Analysis by HPLC-MS/MS
In order to evaluate the stability of the peptides during the activity assay on MP-LM preparations, they were added at 5.0 × 10 -6 M to the organ bath solution, and aliquots were withdrawn at time 0, 4, and 9 min, frozen immediately and kept at − 20 ºC until analysis.
Analysis of the peptides was performed using an Acquity liquid chromatography system (Waters) connected to microToF II Quadrupole-Time-of-Flight mass spectrometer (Bruker). A Waters Acquity UPLC BEH C 18 column 100 mm length, 2.1 mm internal diameter, 1.7 μm packing was used. A binary elution gradient, based on water (solvent A) and acetonitrile 
Molecular modelling receptor-peptide
Homology model of the µ-opioid receptor (UniProtKB -P35372 (OPRM_HUMAN)) was built by standard homology modeling techniques using MODELER version 9.7. (Eswar et al., 2006) , as described in the Supplementary Data. The structure of the human δ-and µ-opioid receptors (Protein Data Bank entries 4RWA and 5C1M) (Fenalti et al., 2015; Huang et al., 2015) were used as template. The structure of the bifunctional δ-opioid antagonist and µ-opioid 
Cell culture
HT29-MTX, a human colon adenocarcinoma-derived mucin-secreting goblet cell line was provided by Dr. Thécla Lesuffleur (Lesuffleur et al., 1993) . The cell line was grown in plastic 75-cm 2 culture flasks in Dulbecco´s Modified Eagle´s medium supplemented with 10% fetal bovine serum and 10 mL/L penicillin-streptomycin solution (all from Gibco, Paisley, UK) at 37 ºC in a 5% CO 2 atmosphere in a humidified incubator. Cells were passaged weekly using trypsin/EDTA 0.05% (Gibco). The culture medium was changed every two days. To study the , and 5.0 × 10 -4 M) was added to the cells and incubated at 37 ºC for 2 to 24 h in a 5% CO 2 humidified atmosphere. The supernatants were collected, frozen and stored at -80 ºC. The total RNA was isolated with Nucleospin® RNA II (Macherey-Nagel, Düren, Germany) according to manufacturer´s instruction.
Quantitative RT-PCR assays (qRT-PCR)
qRT-PCR amplification was carried out using a Lightcycler 480 (Roche, Mannheim, Germany) in 384 wells microplates (Roche). RNA (375 ng) was reverse transcribed using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer´s instruction. For MUC5AC (accession no. AJ001402), target gene, primers 2870-2889/3109-3091 were used. For reference genes human cyclophilin (accession no. Y00052) and human β-actin (accession no. NM_001101) primers 280-304/445-421 and 879-896/1076-1053, respectively, were used (Tai et al., 2008; Zoghbi et al., 2006) . The SYBR Green method was used and each assay was performed with cDNA samples in triplicate. Each reaction tube contained 5 μL 2x
SYBR Green real-time PCR Master Mix (Roche), 0.25 μL of a 10 μM of gene-specific forward and reverse primers, 0.27 μL of cDNA (5.06 ng), and 4.23 μL of water. Amplification was initiated at 95 ºC for 5 min, followed by 45 cycles of 95 ºC for 10 s, 60 ºC for 10 s and 72 ºC for 10 s. Control PCRs were included to confirm the absence of primer dimer formation (notemplate control), and to verify that there was no DNA contamination (without RT enzyme). All real-time PCR assays amplified a single product as determined by melting curve analysis.
Amplification efficiencies of the target and reference genes were performed, and the relative expression levels of the target gene were calculated according to the 2 -ΔΔCt method (Livak & Schmittgen, 2001) . Human cyclophilin and human β-actin were tested as reference gene.
Human cyclophilin gene was then chosen to calculate the threshold cycles because it had previously been shown to be constant under all conditions used. All experiments were performed at least three times in triplicate. Data were analyzed using GraphPad Prism 5.03
software by a two-way ANOVA. For a better comparison of the concentration versus control data for each time, data were analyzed by one-way ANOVA, followed by the Newman-Keuls test. Differences between means and controls with a P value < 0.05 (*), or P value < 0.01 (**)
were considered significant. at a dose 5.5 × 10 -7 M and it was followed by a smooth decrease. As positive controls, β-casomorphin-7 (YPFPGPI) and morphine were used. β-casomorphin-7 showed an increasing trend up to 1.0 × 10 -5 M with a maximum response of 23.3 ± 5.1%, while the morphine inhibition curve increased up to 1.6 × 10 -6 M reaching a 60.6 ± 5.8% of inhibition on the electrically stimulated contractions of the MP-LM preparations. In this latter case, the plateau observed for the highest concentration (5.0 × 10 -6 M) could be due to receptor saturation.
RESULTS
Activity of
However, the decreasing trend of the curves obtained for the α s1 -casein-derived peptides from the third dose led us to consider the possibility of peptide degradation in the organ bath. In order to check peptide stability during the experiments, aliquots of the organ bath were withdrawn at time 0, 4 and 9 min and analysed by HPLC-MS/MS. The chromatographic areas of the extracted molecular ion corresponding to the assayed peptides showed a decrease with the time (Supplementary Figure 1) . The observed decrease in the area of intact peptide was accompanied with the increase of derived peptide fragments, which could be also identified by their fragmentation pattern. , although a concentration decrease ca. 34% and 29% was found from 0 to 9 min, respectively. For these two short peptides, it is possible that although peptide degradation could occur, the derived peptide fragments could not be detected due the short size of the fragments. It has to be noted that some of the new peptide fragments generated by . The positive control, DPDPE, also showed a dose-dependent activity, with the maximum inhibitory effect found at 6 × 10 -8 M (55.3 ± 10.2 %). By the addition of naltrindole (1 × 10 -9 M), a selective δ-opioid receptor antagonist, DPDPE effect was partly reversed (36.0 ± 7.9 %), while the weak activity found for the peptides was not affected.
Molecular modelling of the µ-opioid receptor bound to α s1 -casein peptides
To better understand the opioid activity of these α s1 -casein peptides and aiming to elucidate a structure-activity relationship, molecular dynamics simulations of peptides binding As shown in Table 1 Figure 4E ). However the interaction between the Tyr at the third position and the Gln 61 residue from the receptor changes from van der Waals-type to hydrogen bond-type (Table 1) Figure 4H ).
The interactions of peptide-receptor residues were monitored during the simulation time (45 ns). In case of peptide 144 YFYPEL
149
, interactions with N-terminal Tyr were stable during the simulation, whereas for the rest of residues interactions became stronger as the simulation progressed (Supplementary Figure 3) 
DISCUSSION
β-casomorphins were the first food-derived opioid peptides and were found in a casein hydrolysate in 1979 (Brantl et al., 1979 , which share some structural characteristics with previously described opioid peptides, could also exert this effect. These two sequences, found in a peptic casein hydrolysate, had also demonstrated to stimulate mucin secretion and gene expression in HT29-MTX cells (Martínez-Maqueda et al., 2013a) , and it had been suggested that this effect could be mediated by interaction with μ-opioid receptors (Zoghbi et al., 2006 were able to exert this effect, but only when peptidase inhibitors were added to the preparation.
In view of their structures, opioid peptides have been divided into two groups designated as "typical" and "atypical" (Teschemacher et al., 1997) . "Typical" opioid peptides exhibit the definite N-terminal sequence YGGF, characteristic of the endogenous opioid peptides:
enkephalins, endorphins, and dynorphins. "Atypical" peptides are characterized by the presence of Tyr at the N-terminus which is a structural motif important in ligand-receptor binding, although this N-terminal residue is not present in nociception/orphanin FQ (Reinscheid et al., 1995 , showed naloxoneantagonizable inhibitory effect in the electrically stimulated guinea pig ileum preparation. This isolated tissue possesses both, μ-and κ-opioid receptors that regulate the contractile response when stimulated by inhibiting acetylcholine release during electrical stimulation of the myenteric plexus neurons. Although this preparation also contains cannabinoid, adenosine and adrenergic receptors (Taylor, 2011) , the reversion of the effect by naloxone, a competitive antagonist at μ, δ, and κ-opioid receptors, proved the participation of these receptors on the effect of the assayed peptides. However, lower effects were found in the mouse vas deferens.
This tissue can be used to study all three opioid receptor subtypes, but the expression of μ-and κ-opioid receptors is lower in this preparation than in guinea pig ileum (Taylor, 2011) , being the δ-opioid the predominant receptor subtype (Lord, Waterfield, Hughes, & Kosterlitz, 1977) . The activity of the assayed peptides in mouse vas deferens was not reverted by the use of naltrindole which suggests poor affinity for δ-opioid receptors. Likewise, bovine β-casomorphins have been also demonstrated to exert a higher opioid activity in the guinea pig ileum than in the mouse vas deferens assay (Brantl, Teschemacher, Bläsig, Henschen, & Lottspeich, 1981) . On the contrary, the previously described α s1 -casein exorphins demonstrated a moderated effect on inhibition of adenyl cyclase in neuroblastoma × glioma hybrid cells, as well as, inhibition of contractions in mouse vas deferens, suggesting selectivity for δ-opioid receptors (Loukas et al., 1983) . The assayed peptides show structural homologies with β-casomorphins, with an aromatic residue at the first and third position and a proline residue at the fourth position from the N-terminal. This is in agreement with the higher activity found in the guinea pig ileum preparation. Therefore, further studies with selective opioid antagonists such as β-funaltrexamine, naltrindole, and nor-binaltorphimine for μ-, δ-, and κ-opioid receptors, respectively, are required to evaluate the selectivity of the active peptides found in this study on different receptor subtypes.
Regarding activity, these peptides containing the tripeptide YFY were found to exert an agonist opioid effect on guinea pig ileum preparations, although moderate in strength.
However, it has to be pointed that under our experimental conditions, i.e., application of increasing concentrations at 9 min intervals, peptide β-casomorphin-7, which was used as positive control, did not reach the activity values previously reported in guinea pig ileum preparations, with IC 50 values between 3.2 × 10 -6 and 6.9 × 10 -6 M (Jinsmaa & Yoshikawa, 1999; Koch, Wiedemann, & Teschemacher, 1985; Yoshikawa, Fumito, Takashi, & Hideo, 1986) . The time intervals used in this study were optimized to ensure signal stability. In addition, the stability of the assayed peptides in the organ bath was studied by HPLC-tandem mass spectrometry. It was demonstrated that these peptides were partly hydrolysed by the action of ileum peptidases within 9 min and some of the generated fragments lost the N-terminal Tyr residue characteristic of opioid peptides. In fact, it has been reported that endogenous opioid peptides, with homologous structure than the assayed peptides, are particularly sensitive to rapid hydrolysis by a number of peptidases that are present in the guinea pig ileum, as well as in other tissues (McKnight, Corbett, & Kosterlitz, 1983) . From our results, it was also shown that the shape of the inhibition curve changed by the use of the three peptidase inhibitors but the maximum inhibitory activity did not significantly increase (Figure 1 vs. Figure 2 ). The change in the accumulative inhibition curves, compared to experiments conducted in absence of peptidase inhibitors confirmed that the decrease observed at higher doses in the absence of peptide inhibitors is caused by the peptide degradation during the assay. The combination of these peptidase inhibitors (captopril, amastatin and phosphoramidon 1.0 × 10 -6 M) was not able to change the activity of morphine, DAMGO and metabolically stable synthetic opioid peptides in this preparation (Hiranuma et al., 1998) . Aoki, Kajiwara, and Oka (1984) and McKnigh et al. (1983) -150, 195-200, 240-250 and the C-terminal domain. This structural flexibility is in agreement with previous studies with the μ-opioid receptor (Serohijos et al., 2011) . Similarly, it has been found that morphine leads to a greater flexibility of the third intra-cellular loop of the receptor, which is consistent with the critical role of this loop as the docking site of G-proteins binding (Waldhoer, Bartlett, & Whistler, 2004 found that both peptides establish two strong hydrogen bonds and a charge-charge interaction, in the same way as the morphinan agonist BU72 (Huang et al., 2015) , between the , and 5.0 × 10 -4 M showed increased expression levels over the control, it did not reach significance. There is sufficient literature that illustrates the lack of correlation between μ-opioid potency and effect on mucin secretion or gene overexpression. , and 50 × 10 -6 M, respectively) (Yoshikawa et al., 1986) . Similarly, a recent report has shown that the μ-opioid peptide neocasomorphin-6 (YPVEPF) induced a significant rise in the transmembrane-associated mucin gene MUC4 but without effect on neither the expression of secreted MUC2 and MUC5AC nor the release of mucin-like glycoprotein (Plaisancié et al., 2015) . The effect on mucin production by food protein hydrolysates and peptides appears to be mediated by more than one type of mechanism. It remains to be clarified in any of these antagonized by naloxone, which demonstrates the implication of opioid receptors. The susceptibility of these peptides to be hydrolysed by peptidases found in this tissue was demonstrated by HPLC-tandem mass spectrometry. Several of the resulting fragments lost the N-terminal Tyr residue, and therefore, the potential ability to interact with opioid receptors.
Similarly to β-casomorphins, the assayed peptides exerted opioid activity on mouse vas deferens to a lower extent than in guinea pig ileum. YFY 146 had no effect on MUC5AC expression, although it cannot be discarded activity on other mucin mRNA levels or on mucin secretion. 
